Medical research

Syncromune® Inc. Presents Positive Results from SYNC-T™ SV-102 Phase 1 Trial at AACR Annual Meeting 2024

Retrieved on: 
Monday, April 8, 2024
Failure, Toxicity, Disease, Patient, Nebraska Medicine, University, Cancer research, PRS, Freezing, AACR, Neoplasm, Metastasis, Immune system, ASCO, Medical research, CRS, Pharmaceutical industry

FORT LAUDERDALE, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- Syncromune® Inc., a clinical-stage biopharmaceutical company focused on the development of SYNC-T™, an in situ personalized therapy optimized for solid tumor cancers, today announced the presentation of positive results from the SV-102 Phase 1 trial at the American Association for Cancer Research (AACR) Annual Meeting 2024. The trial, involving patients with metastatic castrate-resistant prostate cancer (mCRPC), showed an overall response rate (ORR) of 85%.        

Key Points: 
  • FORT LAUDERDALE, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- Syncromune® Inc., a clinical-stage biopharmaceutical company focused on the development of SYNC-T™, an in situ personalized therapy optimized for solid tumor cancers, today announced the presentation of positive results from the SV-102 Phase 1 trial at the American Association for Cancer Research (AACR) Annual Meeting 2024.
  • The trial, involving patients with metastatic castrate-resistant prostate cancer (mCRPC), showed an overall response rate (ORR) of 85%.
  • The Phase 1 trial enrolled 15 mCRPC subjects, most of whom had diffuse bone metastases and had experienced failure with prior therapies.
  • The trial is ongoing, with results expected in the second half of 2024.

GTG Global Collaborations and Innovation Update

Retrieved on: 
Tuesday, March 26, 2024
Breast cancer, Health, General practice, Professor, BRCA, Public, Public health, Disease, GTG, Risk, Patient, PRS, Research, ASX, Breast, Mammography, University, Royal Melbourne Hospital, Trial of the century, WHI, Risk assessment, Sonneborn–Berger score, Council, Biobank, Publication, Clinical trial, Cancer, CLIA, Medical research, Colorectal cancer, University of Melbourne, Government, UK Biobank, Pharmaceutical industry

MELBOURNE, Australia, March 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to highlight a summary of the Company’s commitment to innovation.

Key Points: 
  • MELBOURNE, Australia, March 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to highlight a summary of the Company’s commitment to innovation.
  • GTG is one of the co-co-principal investigators of this trial led by Professor Jon Emery.
  • GTG regards adding new expanded risk assessment tests to the company’s portfolio as a critical step in improving patient care.
  • Leveraging this approach GTG is expanding the portfolio with the following new tests:
    Leveraging the BRCA-modifier research projects GTG will develop a test that incorporates high penetrant pathogenic variant risk with PRS.

FORTY-THREE PHYSICIANS FROM UNITED DIGESTIVE PARTNER PRACTICES NAMED CASTLE CONNOLLY TOP DOCTORS 2024

Retrieved on: 
Tuesday, April 9, 2024
Education, Journal, Faculty, Castle Connolly Medical, Gastroenterology, Medical research, Digestive, Physician, Health, Nursing

ATLANTA, April 9, 2024 /PRNewswire/ -- Forty-three physicians from six partner practices of United Digestive have been honored by Castle Connolly as Top Doctors for 2024 for their demonstrated excellence in clinical care, among many other factors.

Key Points: 
  • ATLANTA, April 9, 2024 /PRNewswire/ -- Forty-three physicians from six partner practices of United Digestive have been honored by Castle Connolly as Top Doctors for 2024 for their demonstrated excellence in clinical care, among many other factors.
  • Recipients of the Top Doctors distinction represent the top seven percent of all practicing physicians in the United States.
  • "We are incredibly proud of our 43 physicians who have been recognized as Castle Connolly Top Doctors for 2024," said Dr. Neal C. Patel, CEO of United Digestive.
  • For more information about United Digestive, its partner practices, and Top Doctors recipients, please visit www.uniteddigestive.com .

Blackbaud Institute Shares Spotlight on 2023 Trends in Giving

Retrieved on: 
Monday, April 8, 2024
Online, Millennials, Organization, Philippine Animal Welfare Society, ISO 14000, Software, Blackbaud, Generation Z, Medical research, Gen, Pharmaceutical industry

CHARLESTON, S.C., April 8, 2024 /PRNewswire/ -- The Blackbaud Institute, a research lab at Blackbaud (NASDAQ: BLKB), the leading provider of software for powering social impact, today released new insights from Blackbaud's unmatched philanthropic dataset in its 2023 Trends in Giving Spotlight.

Key Points: 
  • Based on Blackbaud's Robust Philanthropic Data Set, the Blackbaud Institute Shares New Insights on Last Year's Giving Trends and What Fundraisers Should Know for 2024
    CHARLESTON, S.C., April 8, 2024 /PRNewswire/ -- The Blackbaud Institute, a research lab at Blackbaud (NASDAQ: BLKB), the leading provider of software for powering social impact, today released new insights from Blackbaud's unmatched philanthropic dataset in its 2023 Trends in Giving Spotlight.
  • The Blackbaud Institute gives social impact professionals data to understand broader industry trends, benchmark success and take fundraising to new levels.
  • The current spotlight provides a round-up of the charitable giving trends that defined 2023 and a look at the past five years, with tips on how organizations can make the most of this year.
  • "2023 can be seen as a bookend to a historic five-year story of charitable giving, with generosity remaining durable and today's giving levels sustaining well above their pre-pandemic norms."

Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Tuesday, March 19, 2024
Research, Moyamoya disease, Quarter, Cardiovascular disease, Spirited, Growth, Exercise, Entrepreneurship, IL-6, Inflammation, Patient, SVP, Business development, Commercial, NASDAQ Biotechnology Index, MD, IND, Investment, Clinical trial, NBI, Investigational New Drug, Therapy, TRML, Medical research, Graves' ophthalmopathy, FDA, Food, Pharmaceutical industry

In October 2023, Tourmaline become a publicly-traded company via reverse merger with Talaris Therapeutics, including a concurrent private placement of $75.0 million.

Key Points: 
  • In October 2023, Tourmaline become a publicly-traded company via reverse merger with Talaris Therapeutics, including a concurrent private placement of $75.0 million.
  • Fourth Quarter and Full Year 2023 Financial Results:
    Cash, cash equivalents and investments were $203.0 million as of December 31, 2023, as compared to $8.3 million as of December 31, 2022.
  • Research and development expenses were $8.0 million for the fourth quarter of 2023, as compared to $3.8 million for the fourth quarter of 2022.
  • General and administrative expenses were $6.9 million for the fourth quarter of 2023, as compared to $1.1 million for the fourth quarter of 2022.

Feinstein Institutes Secures $6.1M NIH Grant for Red Cell Disorder Research

Retrieved on: 
Wednesday, April 3, 2024
Biotechnology, Health, Science, Pharmaceutical, Research, Diamond, Molecular medicine, Sickle cell disease, Erythropoiesis, Hematology, HMGB1, Cell cycle, Mortality, Doctor of Philosophy, Quality of life, NIH, Diamond–Blackfan anemia, DBA, Credit, Lung, SCD, Medical research, Anemia, Bangladesh Technical Education Board, Multimedia, Conditional sentence, Pharmaceutical industry

To further our understanding and potential treatments of these disorders, The Feinstein Institutes for Medical Research has been awarded a $6.1 million grant from the National Institutes of Health (NIH).

Key Points: 
  • To further our understanding and potential treatments of these disorders, The Feinstein Institutes for Medical Research has been awarded a $6.1 million grant from the National Institutes of Health (NIH).
  • View the full release here: https://www.businesswire.com/news/home/20240403646471/en/
    Dr. Lionel Blanc will lead the new NIH-funded red cell disorders research (Credit: Feinstein Institutes)
    Led by Lionel Blanc, PhD , professor in the Institute of Molecular Medicine at the Feinstein Institutes, the seven-year initiative aims to build off previous research and will shed light on DBA, SCD and anemia.
  • “Understanding red cell blood disorders, how they develop and progress, is essential given their global impact on millions,” said Dr. Blanc.
  • In 2019, he received a $2.5 million grant from the NIH to study treatment for erythropoietic disorders, including DBA.

Rachael Brake, PhD, Joins Zephyr AI as Chief Scientific Officer

Retrieved on: 
Tuesday, April 2, 2024
Cardiology, Data Management, Biotechnology, Technology, Health, Pharmaceutical, Oncology, Health Technology, Software, Artificial Intelligence, Clinical Trials, Translational research, Australian National University, Communication, Corbus, Associate, Takeda Oncology, University, Research, Artificial intelligence, Cancer, Head, Doctor of Philosophy, Molecular biology, Medicine, Biochemistry, Brake, Takeda, Medical research, Interim, Multimedia, Zephyr, Medical device

Zephyr AI, Inc. (“Zephyr AI”), a healthcare technology company committed to developing fast and explainable artificial intelligence (AI) solutions to democratize precision medicine, today announced the appointment of Rachael Brake, PhD, as its new Chief Scientific Officer.

Key Points: 
  • Zephyr AI, Inc. (“Zephyr AI”), a healthcare technology company committed to developing fast and explainable artificial intelligence (AI) solutions to democratize precision medicine, today announced the appointment of Rachael Brake, PhD, as its new Chief Scientific Officer.
  • View the full release here: https://www.businesswire.com/news/home/20240401145891/en/
    “Having spent decades working in big pharma and biotech spanning roles in research, development and commercial, Rachael comes to Zephyr with a unique breadth of experience,” said Jeff Sherman, Zephyr AI Co-Founder, Interim CEO, and Chief Technology Officer.
  • Prior to her work at Corbus, Brake spent 11 years at Takeda Oncology, most recently as Head of U.S. Medical Affairs Oncology.
  • I’m thrilled to be joining the incredibly talented Zephyr AI team at such a pivotal time in clinical research.”

Bioelectronic medicine Feinstein Institutes researchers elected to AIMBE College of Fellows

Retrieved on: 
Monday, March 25, 2024
Health, Health Insurance, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Vagus nerve, Metabolism, Interdisciplinarity, Biomedical engineering, Brain, Sepsis, Rheumatoid arthritis, Medicine, Mevalonate pathway, Interface (computing), Communication, International Society, Disease, Paralysis, Diabetes, Education, Inflammation, Pulmonary hypertension, Nervous system, Class, PNAS, Cancer, Neuroscience, Doctor of Philosophy, AIMBE, Neuron, Inflammatory Bowel Diseases, Arthritis, Credit, Northwell Health, American Institute, Molecular medicine, Sensation, Infection, DRS, Immune system, Injury, Medical research, Inflammatory bowel disease, Biology, Multimedia, National academy, Government, ISAN, Medical device

The American Institute for Medical and Biological Engineering (AIMBE) has announced the election of two researchers from The Feinstein Institutes for Medical Research to the AIMBE College of Fellows Class of 2024 for their contributions to the fields of medical and biological engineering, and particularly the field of bioelectronic medicine.

Key Points: 
  • The American Institute for Medical and Biological Engineering (AIMBE) has announced the election of two researchers from The Feinstein Institutes for Medical Research to the AIMBE College of Fellows Class of 2024 for their contributions to the fields of medical and biological engineering, and particularly the field of bioelectronic medicine.
  • Valentin Pavlov, PhD , and Sangeeta Chavan, PhD , both professors in the Institute of Bioelectronic Medicine , were recognized in-person during the AIMBE Annual Event in Washington D.C..
  • Sangeeta Chavan (left) and Valentin Pavlov (right) have been elected to the AIMBE College of Fellows for advancing the fields of medical and biological engineering.
  • On behalf of the Feinstein Institutes and Northwell Health, we congratulate them.”
    The Feinstein Institutes for Medical Research is the global scientific home of bioelectronic medicine where medical researchers use modern technology to develop new device-based therapies to treat disease and injury.

Northwell Health’s Feinstein Institutes for Medical Research establishes first Professor in Women’s Health Research, boosting national movement to close gender gaps

Retrieved on: 
Tuesday, March 19, 2024
Research, Philanthropy, Oncology, Consumer, Hospitals, Fund Raising, Foundation, Science, Surgery, Women, Nursing, Health, Hospital, RN, Growth, Celebration, Health equity, Physician, Doctor of Philosophy, Barack Obama, Personalized medicine, Life, Medicine, Woman, North Shore University Hospital, Credit, Glen Cove Hospital, Katz, Medical research, Multimedia, FAAN, Feinstein, SHE, Impossible

Thanks to a generous endowment from women’s health advocates and philanthropists Iris and Saul Katz, Northwell Health and its home of medical research, the Feinstein Institutes for Medical Research , have established the Iris and Saul Katz Professor in Women’s Health Research in response to a national movement aimed at addressing the health care disparities facing women.

Key Points: 
  • Thanks to a generous endowment from women’s health advocates and philanthropists Iris and Saul Katz, Northwell Health and its home of medical research, the Feinstein Institutes for Medical Research , have established the Iris and Saul Katz Professor in Women’s Health Research in response to a national movement aimed at addressing the health care disparities facing women.
  • “While women’s health is now recognized as a national priority, Northwell has been addressing this issue for more than 15 years by creating solutions to close health gaps through the Katz Institute for Women’s Health , a network of more than 750 dedicated women’s health experts,” said Stacey E. Rosen, MD , executive director of the Katz Institute for Women’s Health, senior vice president of women’s health at Northwell and the Partners Council Professor of Women’s Health.
  • With more than 25 years of experience at North Shore University Hospital (NSUH) in Manhasset, she specializes in health equity, precision medicine and community-engaged research.
  • Cohn is highly regarded as a nurse-scientist and a champion for women’s health and medical research,” said Kevin J. Tracey, MD , president and CEO of the Feinstein Institutes and the Karches Family Distinguished Chair in Medical Research.

ECONOMY AND POLITICS AFFECT IMPACT INVESTORS

Retrieved on: 
Wednesday, March 27, 2024
Online, Culture, Generation X, Global health, Education, Ageing, Research, American Century Investments, American Century, Investment, Medical research, Century, Gen

KANSAS CITY, Mo., March 27, 2024 /PRNewswire/ -- In the seventh impact investing survey by the $240 billion* global asset manager American Century Investments, U.S. investors buck international trends as the only surveyed country where a growing number of respondents are willing to sacrifice returns to create a positive impact. Yet, the appeal of impact investing has declined in each country surveyed, including the U.S. The survey results offer multiple reasons for this decline in appeal, including market conditions, concerns about greenwashing and the sustainability backlash. Survey results go back to 2016 in the United States, 2019 in the U.K., 2020 in Germany, 2021 in Australia and 2022 in Singapore.

Key Points: 
  • 40% of U.S. respondents are willing to sacrifice returns in order to create a positive impact.
  • Overall, 67% of interested investors would sacrifice up to 10% of returns to create a positive impact, with 6-10% the most common range.
  • "In its earliest forms, impact investing often accepted lower expected returns to have a bigger impact, but our impact investment strategies emphasize sustainability-related attributes or outcomes in addition to delivering a financial return.
  • "A willingness to give up as much as 10% of an expected return shows that impact investors expect to earn competitive returns and are making rational choices to realize an impact emphasis in addition to a financial return."